RESUMO
Immunoglobulin (Ig) against Marburg fever (MF) has been obtained from the equine serum. In terms of physicochemical and immunobiological properties, the obtained preparation corresponds to the quality of heterologous commercial immunoglobulins. The application of Marburg virus (MV) Ig with a titer of no less than 1:2048 by the emergency prevention scheme 1-2 hours after intraperitoneal inoculation of guinea pigs with MV in a dose of 20-50 LD50 protected 88-100% of the animals from death. MV Ig is recommended for emergency prevention of human MF.
Assuntos
Anticorpos Antivirais/imunologia , Cavalos , Imunização , Imunoglobulinas/imunologia , Doença do Vírus de Marburg/sangue , Marburgvirus/imunologia , Animais , Anticorpos Antivirais/sangue , Especificidade de Anticorpos , Cobaias , Imunoglobulinas/administração & dosagem , Imunoglobulinas/sangue , Injeções Intraperitoneais , Doença do Vírus de Marburg/prevenção & controle , Camundongos , Testes de Neutralização , Papio , Coelhos , Fatores de TempoRESUMO
A horse may serve the producer of immune antiserum to Lassa virus. Specific immunoglobulin with at least 1:512 titer of virus-neutralizing antibodies to Lassa fever was obtained by alcohol sedimentation after Cohn from the blood serum of immunized horses. The preparation does not differ from heterologous commercial immunoglobulins. Preclinical studies of immunoglobulin to Lassa fever demonstrated its safety and a high specific activity. The agent can be injected both alone and in combination with virasole.
Assuntos
Imunoglobulinas/biossíntese , Febre Lassa/prevenção & controle , Vírus Lassa/imunologia , Animais , Cavalos , Soros Imunes , Febre Lassa/tratamento farmacológico , Testes de Neutralização , Ribavirina/uso terapêutico , Vacinas Virais/uso terapêuticoRESUMO
The authors validate the use of horses as producers of immune antiserum to Lassa virus. Specific immunoglobulin with at least 1:512 titer of virus neutralizing antibodies to Lassa virus was obtained from the serum of immunized horses by Kohn's alcohol method. The resultant preparation does not differ from the heterologous commercial immunoglobulins. Preclinical studies of immunoglobulin against Lassa virus demonstrated its safety and high specific activity. The strategy of treating with the immunoglobulin alone and in combination with virasol has been experimentally validated.
Assuntos
Anticorpos Antivirais/biossíntese , Arenavirus/imunologia , Imunoglobulinas/biossíntese , Febre Lassa/imunologia , Animais , Anticorpos Antivirais/imunologia , Antivirais/uso terapêutico , Arenavirus do Velho Mundo/imunologia , Linhagem Celular , Chlorocebus aethiops , Cavalos , Soros Imunes , Imunização Passiva , Imunoglobulinas/imunologia , Febre Lassa/terapia , Ribavirina/uso terapêuticoRESUMO
An enzyme immunoassay system has been developed for the detection of Ebola virus antigen. It permits a highly accurate and sensitive rapid detection of the antigen. Optimal dilutions of specific immunoglobulin (1:500, corresponding to protein concentration of 50 micrograms/ml) and conjugate were found. The resolving capacity of the new test system is 1.9 x 10(-7) g protein.
Assuntos
Antígenos Virais/análise , Ebolavirus/imunologia , Técnicas Imunoenzimáticas , Animais , Haplorrinos , Sensibilidade e EspecificidadeRESUMO
Immunoglobulin to Ebola fever has been for the first time prepared from hyperimmune equine blood sera by alcohol fractionation after Cohn. Preclinical study of the physicochemical and immunobiological properties of immunoglobulin showed that it protects up to 100% Papio hamadryas infected intramuscularly at doses of 110 to 29 LD50 Ebola virus. Scheme for the use of Ebola immunoglobulin has been experimentally validated.
Assuntos
Doença pelo Vírus Ebola/terapia , Imunoglobulinas/uso terapêutico , Animais , Anticorpos Antivirais/biossíntese , Relação Dose-Resposta Imunológica , Cobaias , Soros Imunes , Imunoglobulinas/imunologia , Camundongos , Papio , CoelhosAssuntos
Vírus Lassa/imunologia , Vacinas Virais/isolamento & purificação , Animais , Chlorocebus aethiops , Relação Dose-Resposta Imunológica , Avaliação Pré-Clínica de Medicamentos , Imunização/métodos , Febre Lassa/prevenção & controle , Papio , Fatores de Tempo , Vacinas de Produtos Inativados/imunologia , Vacinas de Produtos Inativados/isolamento & purificação , Células Vero , Vacinas Virais/imunologia , Viremia/prevenção & controleRESUMO
The protective role of virus-neutralizing antibody was demonstrated in Ebola virus-infected animals (Papio hamadryas) used in experiments on the development of passive humoral immunity by using specific immunoglobulin. Two immunizations of the monkeys with purified concentrated Ebola virus antigen with complete Freund adjuvant was shown to confirm intensive immunity to subsequent challenge protecting 80% of the immunized animals. It is concluded that effective preparations may be developed for specific prophylaxis of Ebola fever.
Assuntos
Ebolavirus , Febres Hemorrágicas Virais/prevenção & controle , Doenças dos Macacos/prevenção & controle , Animais , Anticorpos Antivirais/sangue , Especificidade de Anticorpos , Antígenos Virais/imunologia , Antígenos Virais/isolamento & purificação , Ebolavirus/imunologia , Feminino , Febres Hemorrágicas Virais/imunologia , Imunização/métodos , Imunoglobulinas/imunologia , Imunoglobulinas/isolamento & purificação , Masculino , Doenças dos Macacos/imunologia , Papio , Fatores de TempoRESUMO
A single and double immunization of Papio hamadryas monkeys with an inactivated concentrated purified adsorbed preparation of Lassa virus in doses of 0.5-1.0 and 1.1-2.1 mg by protein, respectively, protected the animals against the development of the disease and occurrence of viremia after an intramuscular challenge with 0.4 PFU dose. Upon aerogenic infection of monkeys protection of 50% of the animals was achieved by a single immunization with the inactivated preparation in a dose 1.1 mg by protein.
Assuntos
Vírus Lassa/imunologia , Vacinas Virais/isolamento & purificação , Animais , Anticorpos Antivirais/sangue , Testes de Fixação de Complemento , Relação Dose-Resposta Imunológica , Avaliação Pré-Clínica de Medicamentos , Imunização , Febre Lassa/imunologia , Febre Lassa/mortalidade , Febre Lassa/prevenção & controle , Vírus Lassa/isolamento & purificação , Testes de Neutralização , Papio , Fatores de Tempo , Vacinas de Produtos Inativados/imunologia , Vacinas de Produtos Inativados/isolamento & purificação , Vacinas Virais/imunologia , Cultura de VírusRESUMO
The biochemical and immunochemical study of the qualitative composition of R. prowazekii antigenic preparations, isolated and purified by different methods, indicates that these preparations contain high-molecular polypeptide 3 (133600 D), morphologically linked with the cell membrane of R. prowazekii. The method of adsorption chromatography on calcium phosphate permits obtaining specific rickettsial antigens with a greater degree of purification from ballast admixtures than the methods of acid precipitation and gel filtration on Sephadex G-200.